Payment overview · 2025
General Payments
$1,570.73
78 reported records · 15 companies
Healthcare provider profile · identity verified
Ralph Michael Tucker, MD
Allopathic & Osteopathic Physicians|Family Medicine · LEHIGH ACRES, FL · NPI 1497742936
Verified facts
What the public records show
CMS Open Payments records show Ralph Michael Tucker, MD received $1,570.73 in general payments during 2025 across 78 reported records.
Novo Nordisk Inc accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $301.28 | 19.2% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $239.29 | 15.2% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $198.14 | 12.6% | 10 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $147.63 | 9.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.36 | 9.1% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.65 | 7.2% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $91.56 | 5.8% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $64.83 | 4.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.76 | 3.8% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.37 | 3.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.32 | 3.1% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $36.88 | 2.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.41 | 2.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.69 | 1.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.56 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,570.73 | 78 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $239.29 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $237.75 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $237.75 | 12 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $147.63 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $117.77 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $91.56 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $80.37 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $80.37 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $72.22 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $72.22 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $70.14 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $64.83 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $59.76 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $57.37 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $57.06 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.59 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $55.59 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.56 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $36.88 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 105 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 50 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 531 | 150 |
| Lisinopril | Lisinopril | 407 | 110 |
| Omeprazole | Omeprazole | 361 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 352 | 99 |
| Alprazolam | Alprazolam | 340 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 326 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 242 | 78 |
| Losartan Potassium | Losartan Potassium | 237 | 74 |
| Gabapentin | Gabapentin | 206 | 47 |
| Tramadol Hcl | Tramadol Hcl | 206 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 63 |
| Montelukast Sodium | Montelukast Sodium | 180 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 54 |
| Simvastatin | Simvastatin | 153 | 37 |
| Azithromycin | Azithromycin | 151 | 103 |
| Torsemide | Torsemide | 149 | 61 |
| Metformin Hcl | Metformin Hcl | 148 | 40 |
| Famotidine | Famotidine | 144 | 49 |
| Furosemide | Furosemide | 127 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 41 |
| Ozempic | Semaglutide | 119 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 29 |
| Methylprednisolone | Methylprednisolone | 111 | 78 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 36 |
| Allopurinol | Allopurinol | 107 | 35 |
| Lorazepam | Lorazepam | 107 | 36 |
| Ezetimibe | Ezetimibe | 106 | 43 |
| Eliquis | Apixaban | 105 | 23 |
| Glimepiride | Glimepiride | 101 | 31 |
| Alendronate Sodium | Alendronate Sodium | 98 | 29 |
| Potassium Chloride | Potassium Chloride | 95 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 93 | 57 |
| Finasteride | Finasteride | 93 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 26 |
| Sertraline Hcl | Sertraline Hcl | 87 | 22 |
| Januvia | Sitagliptin Phosphate | 86 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 24 |
| Naproxen | Naproxen | 83 | 39 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 79 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 15 |
| Terazosin Hcl | Terazosin Hcl | 76 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 29 |
| Mupirocin | Mupirocin | 75 | 41 |
| Donepezil Hcl | Donepezil Hcl | 73 | 16 |
| Carvedilol | Carvedilol | 72 | 19 |
| Xarelto | Rivaroxaban | 72 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 71 | 14 |
| Trazodone Hcl | Trazodone Hcl | 69 | 13 |
| Celecoxib | Celecoxib | 67 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 15 |
| Memantine Hcl | Memantine Hcl | 60 | 12 |
| Myrbetriq | Mirabegron | 58 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 31 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 57 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 22 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Prednisone | Prednisone | 54 | 35 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 53 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 11 |
| Glipizide | Glipizide | 53 | 15 |
| Jardiance | Empagliflozin | 50 | 15 |
| Lovastatin | Lovastatin | 48 | 15 |
| Pregabalin | Pregabalin | 48 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 34 |
| Atenolol | Atenolol | 46 | 13 |
| Azelastine Hcl | Azelastine Hcl | 46 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 11 |
| Cephalexin | Cephalexin | 43 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Meloxicam | Meloxicam | 41 | 18 |
| Venlafaxine Hcl | Venlafaxine Hcl | 40 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 38 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 17 |
| Sucralfate | Sucralfate | 37 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 14 |
| Ondansetron Odt | Ondansetron | 36 | 16 |
| Valsartan | Valsartan | 35 | 12 |
| Fenofibrate | Fenofibrate | 34 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | 18 |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 19 |
| Nystatin | Nystatin | 32 | 14 |
| Temazepam | Temazepam | 32 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 18 |
| Carisoprodol | Carisoprodol | 27 | 12 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Folic Acid | Folic Acid | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | 12 |
| Cholestyramine Light | Cholestyramine | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | 11 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 11 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,570.73 · 78 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, Assure WCD, Auvelity, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, EVENITY, JARDIANCE, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, XYOSTED, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error